Akzo Signed Biotech Supply Agreement
Advertisement
Akzo Nobel's Diosynth Biotechnology business has signed a supply agreement with the Dutch-based Pharming Group for the production of recombinant human C1 inhibitor (rhC1INH) for commercial use. The agreement enables Pharming to prepare for the market launch of rhC1INH for the treatment of hereditary angioedema, a life threatening genetic disorder caused by a deficiency of the C1 inhibitor protein.
Under the terms of the deal, Diosynth Biotechnology is responsible for technology transfer, purification-process development, scaling-up and the commercial production of Pharming's rhC1INH at its large-scale downstream processing facility in Oss, the Netherlands. The facility has been FDA inspected and currently produces commercial products. The financial terms of the agreement have not been disclosed.